Boothbay Fund Management’s BioRestorative Therapies BRTX Stock Holding History

Boothbay Fund Management’s Portfolio BRTX Stock Details BRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12,296	Closed	-$33.8K	–	2150
2022 Q4	$33.8K	Sell	12,296 -19,704	-62%	-$61.4K	﹤0.01%	1902
2022 Q3	$103K	Hold	32,000	–	–	﹤0.01%	2029
2022 Q2	$94K	Sell	32,000 -8,000	-20%	-$33.9K	﹤0.01%	1997
2022 Q1	$209K	Sell	40,000 -23,984	-37%	-$103K	﹤0.01%	1854
2021 Q4	$278K	Buy	+63,984	New	+$365K	0.01%	1304

Other funds holding BRTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Boothbay Fund Management's BRTX Position: Q1 2023 in Review

Boothbay Fund Management sold out of BioRestorative Therapies (BRTX) in Q1 2023, closing a stake of 12,296 shares — an estimated $33.8K sold.

Boothbay Fund Management first reported a position in BRTX in Q4 2021 and held it in 5 quarters. The position peaked at $278K in Q4 2021. 14 funds tracked by Wall St. Rank hold BRTX as of Q1 2023.

Boothbay Fund Management reported no remaining BioRestorative Therapies position as of Q1 2023 after selling out during the quarter.
Boothbay Fund Management sold 12,296 BioRestorative Therapies shares in Q1 2023, an estimated $33.8K.
Boothbay Fund Management first reported a position in BioRestorative Therapies in Q4 2021 and held it in 5 quarters.
Boothbay Fund Management's BioRestorative Therapies position peaked at $278K in Q4 2021.
14 funds tracked by Wall St. Rank held BioRestorative Therapies as of Q1 2023.

Based on Boothbay Fund Management's 13F filing for Q1 2023, filed 15 May 2023.